Trial Profile
A phase II Open Label, two-armed Translational Study of Nivolumab in Combination with Bevacizumab for Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Biomarker; Pharmacodynamics
- Acronyms Nivo-Bev-ITT-01
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 25 Oct 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 25 Oct 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Feb 2023.